Nanomedicines as Drug Delivery Carriers of Anti-Tubercular Drugs: From Pathogenesis to Infection Control.

Nanomedicines as Drug Delivery Carriers of Anti-Tubercular Drugs: From Pathogenesis to Infection Control.
Curr Drug Deliv. 2019 Feb 01;:
Authors: Hussain A, Singh S, Das SS, Anjireddy K, Karpagam S, Shakeel F
Abstract
In spite of advances in tuberculosis (TB) chemotherapy, TB is still air-born deadly disorder as major issue of health concern worldwide today. Extensive researches have been focused to develop novel drug delivery systems to shorten the lengthy therapy approaches, prevention of relapses, reducing dose related toxicities and to rectify technological related drawbacks of anti-tubercular drugs. Moreover, rapid emergence of drug resistance, poor patient compliance due to negative therapeutic outcomes and intracellular survival of Mycobacterium highlighted to develop carrier with optimum effectiveness of the anti-tubercular drugs. This could be achieved by targeting and concentrating the drug to the infection reservoir of Mycobacterium. In this article, we briefly compiled the general aspects of Mycobacterium pathogenesis, disease treatment along with progressive updates in novel drug delivery carrier system to enhance therapeutic effectiveness of drug and the high level of patient compliance. Recently developed several vaccines might be shortly available as reported by WHO.
PMID: 30714523 [PubMed - as supplied by publisher]

Source: Current Drug Delivery - February 1, 2019 Category: Drugs & Pharmacology Authors: Hussain A, Singh S, Das SS, Anjireddy K, Karpagam S, Shakeel F Tags: Curr Drug Deliv Source Type: research